Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment

Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?

(2014) Adriana Balduzzi et al.   BRITISH JOURNAL OF HAEMATOLOGY

ALL-REZ BFM - The Consecutive Trials for Children with Relapsed Acute Lymphoblastic Leukemia

(2013) G. Henze et al.   KLINISCHE PADIATRIE

Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia

(2012) W. Leung et al.   BLOOD

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

(2012) M. Klinger et al.   BLOOD

Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia – Long-term results of trial ALL-REZ BFM P95/96

(2012) Cornelia Eckert et al.   EUROPEAN JOURNAL OF CANCER

High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia

(2011) W. Leung et al.   BLOOD

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

(2011) R. J. Brentjens et al.   BLOOD

Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90

(2010) Gesche Tallen et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial

(2010) Catriona Parker et al.   LANCET

Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia

(2010) R Handgretinger et al.   LEUKEMIA

Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials

(2008) A Schrauder et al.   BONE MARROW TRANSPLANTATION

Reinduction Platform for Children With First Marrow Relapse of Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

(2008) Elizabeth A. Raetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group

(2008) Peter Bader et al.   JOURNAL OF CLINICAL ONCOLOGY

Bone-marrow relapse in paediatric acute lymphoblastic leukaemia

(2008) L Charles Bailey et al.   LANCET ONCOLOGY

Minimal residual disease is an important predictive factor of outcome in children with relapsed ‘high-risk’ acute lymphoblastic leukemia

(2008) M Paganin et al.   LEUKEMIA

Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study

(2008) K Nguyen et al.   LEUKEMIA